Charcot-Marie-Tooth (CMT) is a group of inherited conditions that affect the nerves in the arms and legs. It can cause muscle weakness, trouble walking, balance problems, and fatigue. There are currently no approved medical treatments specifically for CMT. Researchers are looking for new ways to help improve how nerves and muscles communicate.
The 
Study
For Adults Living With Type 1 and Type 2 Charcot-Marie-Tooth Disease
What Is Charcot-Marie-Tooth?
About NMD 670
NMD670 is an oral investigational medicine that aims to help muscles respond better to nerve signals in CMT.
It is taken as 2 tablets twice a day with water. It works differently from other treatments or recommendations that a doctor or therapist may provide for CMT, such as medications, braces, or physical therapy, and should be discussed with your doctor.
This approach could reduce symptoms that you have regarding muscle weakness and fatigue, increasing muscle strength, power, and endurance throughout the day. NMD670 is not yet approved and is being studied to ensure safety and effectiveness.
About the CMT Clinical Trial
The purpose of this clinical trial is to study the safety and effects of NMD670 in adults with CMT.
What does participation include?
- Taking oral tablets twice daily for about 8 weeks
- At least 6 in-person study visits over about 8 weeks, lasting between 4-6 hours
- Testing, which may include physical exams, lab work, heart tests, mobility assessments, and questionnaires
- Study participants have a 50% chance of receiving NMD670 and a 50% chance of receiving placebo (a sugar pill) during the study
What else should I know?
- Travel costs may be reimbursed, with possible compensation for time or lost wages
- Participation is voluntary and at no cost
Who is eligible?
- Adults aged 18–70
- Those with a confirmed genetic diagnosis of CMT 1 or CMT 2 (not including CMT 1X)
- Able to do physical tests without an ankle/foot brace (orthopedic inserts allowed)
Enrollment is Now Closed
Thank you to all 80 CMT patients who volunteered and participated in this clinical study!
Stay tuned for updates on upcoming clinical studies for Charcot-Marie-Tooth disease across a broad patient population.
Continue to learn more